NASDAQ | ETF
The fund's manager will invest at least 80% of its net assets (plus any borrowings for investment purposes) in the equity securities of GLP-1 & Weight Loss Companies or any derivative instruments (such as swap agreements or forward contracts) that utilize one or more GLP-1 & Weight Loss Companies as the reference asset.
The fund is non-diversified.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| LLY | Eli Lilly and Company | Healthcare | Drug Manufacturers - General | 16.74% |
| NVO | Novo Nordisk A/S | Healthcare | Drug Manufacturers - General | 13.30% |
| TERN | Terns Pharmaceuticals Inc | Healthcare | Biotechnology | 8.53% |
| PFE | Pfizer Inc | Healthcare | Drug Manufacturers - General | 7.07% |
| VKTX | Viking Therapeutics Inc | Healthcare | Biotechnology | 5.64% |
| 1801 | Innovent Biologics Inc | Healthcare | Biotechnology | 4.82% |
| 1672 | Ascletis Pharma Inc | Healthcare | Biotechnology | 4.22% |
| AMGN | Amgen Inc | Healthcare | Drug Manufacturers - General | 4.03% |
| ROG | Roche Holding AG | Healthcare | Drug Manufacturers - General | 3.97% |
| MTSR | Metsera, Inc. Common Stock | Healthcare | Biotechnology | 3.90% |
| 4519 | Chugai Pharmaceutical Co. Ltd. | Healthcare | Drug Manufacturers - General | 3.69% |
| AZN | AstraZeneca PLC | Healthcare | Drug Manufacturers - General | 3.60% |
| 128940 | Hanmi Pharm Co Ltd | Healthcare | Drug Manufacturers - Specialty & Generic | 3.50% |
| REGN | Regeneron Pharmaceuticals Inc | Healthcare | Biotechnology | 3.15% |
| ZEAL | Zealand Pharma A/S | Healthcare | Biotechnology | 3.14% |
| 2196 | Shanghai Fosun Pharmaceutical Group Co Ltd | Healthcare | Drug Manufacturers - Specialty & Generic | 3.12% |
| AZN | AstraZeneca PLC | Healthcare | Drug Manufacturers - General | 3.05% |
| AZN_old | AstraZeneca PLC | Healthcare | Drug Manufacturers - General | 3.05% |
| 3933 | United Laboratories International Holdings Ltd | Healthcare | Drug Manufacturers - Specialty & Generic | 2.98% |
| 1093 | CSPC Pharmaceutical Group Ltd | Healthcare | Drug Manufacturers - General | 2.73% |